Experts provide advice on government funded research
so studies will satisfy both sceptics and believers
TORONTO, Nov. 3, 2011 /CNW/ - Today the CCSVI Coalition announced its
Scientific Advisory Board (SAB). The advisory group of diagnostic,
treatment and pathology experts has extraordinary insight into CCSVI
and MS and a wealth of practical experience in assessing and treating
people with CCSVI. They have been assembled to be an expert resource
for researchers and government on these issues and to facilitate a
balanced and open dialogue regarding CCSVI and MS.
The CCSVI Coalition Scientific Advisory Board of experts includes:
Dr. Bill Code, Duncan, BC, Can - MD and chronic pain specialist
Dr. Mark Godley, Vancouver, BC, Can - anaesthesiology, cross discipline medical
Dr. Sandy McDonald, Barrie, ON, Can. - Cardiovascular & thoracic surgeon; Dopler
Dr. Mark Haacke, Detroit Mich, USA - Phd, MR research & MRV protocols
Dr. David Hubbard, San Diego Calif., USA - MD, neurologist & sponsor CCSVI multi-centre
Dr. Salvatore Sclafani, Brooklyn, NY USA, Interventional Radiologist; Intravascular Ultra
Dr. Gary Siskin, Albany, NY, USA - Interventional Radiologist; CCSVI safety co-author
Taken together, Drs. Sclafani and Siskin have performed over 400 CCSVI
treatments as practicing Interventional Radiologists.
The Scientific Advisory Board is Chaired by Dr. Michael E. Shannon, an acknowledged expert in designing and running large clinical trials.
He is well known to government and medical experts in Canada through
his past positions as Deputy Surgeon General, Director General of The
Laboratory Centers for Disease Control and Senior Medical Advisor to
the Canadian Public Health Agency.
"We are delighted that there are to be CCSVI trials in Canada. This is
an exciting new area of study that has aroused many hopes and much
controversy," said Dr. Michael Shannon. "We wish to contribute
constructively to the process of preparing an RFP for the Phase I/II
trial for CCSVI and MS by offering our expert help to the Canadian
Institutes of Health Research and Health Canada to make the trials the
best they possibly can be."
In a letter to the CIHR, the CCSVI Coalition SAB highlighted key issues
and recommendation inclusions for a detailed RFA or RFP to be issued by
the CIHR. These issues relate to diagnostics, treatment and post
treatment care regimes and represent new insights in the growing body
of practical knowledge in the CCSVI field.
"The CCSVI Coalition Scientific Advisory Board has a depth of knowledge
and expertise second to none in the area of CCSVI diagnosis and
treatment." explained Dr, Shannon. "Canada has the opportunity to
become a leader in the understanding of how the venous system affects a
debilitating neurological disease. The implications for people with MS
could be life changing, and the possibilities to learn about other
neurological disorders have immeasurable potential benefit."
"We offer our expertise to help ensure that the trials will be, and will
be seen to be, robust enough to satisfy all interested parties despite
the diversity and disagreements in their current opinions. This is a
rare expertise that can make a significant contribution to the CIHR
In June 2011, the Government of Canada on the unanimous advice of the
CIHR approved funding for clinical trials of CCSVI related to Multiple
Biographies of SAB members can be found at http://ccsvicoalition.org/scientific-advisory-board.
The CCSVI Coalition (www.ccsvicoalition.org) is a not-for-profit corporation, founded to encourage education and
research into CCSVI as it relates to all neurological diseases,
including Multiple Sclerosis. The founding members of the group were
partly responsible for securing funding for the St. Joseph's and
McMaster research project relating to CCSVI. Some are also a part of
the Multiple Sclerosis Society of Canada's CCSVI Working Group, a group
that has been tasked to advise the MS Society's Board regarding CCSVI.
SOURCE CCSVI Coalition
For further information:
Media Contact: Victoria Ollers firstname.lastname@example.org, (416) 822-2288